CVS Health Corporation (NYSE:CVS) CFO David M. Denton sold 237,078 shares of the company’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $79.65, for a total value of $18,883,262.70. Following the completion of the sale, the chief financial officer now owns 141,096 shares in the company, valued at approximately $11,238,296.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
CVS Health Corporation (NYSE CVS) traded up 3.40% during midday trading on Tuesday, hitting $82.43. The company had a trading volume of 8,048,272 shares. CVS Health Corporation has a 52-week low of $69.30 and a 52-week high of $91.82. The stock has a market cap of $83.80 billion, a PE ratio of 16.42 and a beta of 0.92. The stock’s 50-day moving average price is $78.40 and its 200-day moving average price is $78.90.
CVS Health Corporation (NYSE:CVS) last posted its earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.02. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The firm had revenue of $45.69 billion for the quarter, compared to analyst estimates of $45.36 billion. During the same quarter in the prior year, the company earned $1.32 EPS. CVS Health Corporation’s revenue was up 4.5% on a year-over-year basis. On average, equities research analysts expect that CVS Health Corporation will post $5.88 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/09/12/cvs-health-corporation-cvs-cfo-sells-18883262-70-in-stock.html.
Hedge funds have recently bought and sold shares of the stock. Pathstone Family Office LLC lifted its stake in CVS Health Corporation by 341.0% in the 2nd quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock valued at $2,353,000 after buying an additional 982 shares in the last quarter. Fieldpoint Private Securities LLC lifted its stake in CVS Health Corporation by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 1,000 shares in the last quarter. Mercer Capital Advisers Inc. purchased a new stake in CVS Health Corporation in the 1st quarter valued at approximately $118,000. TB Alternative Assets Ltd. purchased a new stake in CVS Health Corporation in the 2nd quarter valued at approximately $121,000. Finally, Gemmer Asset Management LLC lifted its stake in CVS Health Corporation by 15.3% in the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock valued at $121,000 after buying an additional 200 shares in the last quarter. 81.55% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have recently commented on CVS. Needham & Company LLC restated a “hold” rating on shares of CVS Health Corporation in a research note on Sunday. BidaskClub downgraded CVS Health Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 25th. Loop Capital started coverage on CVS Health Corporation in a research report on Thursday, August 24th. They set a “hold” rating and a $83.00 price target on the stock. Citigroup Inc. lowered their price target on CVS Health Corporation from $88.00 to $87.00 and set a “neutral” rating on the stock in a research report on Thursday, August 17th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $90.00 price target on shares of CVS Health Corporation in a research report on Monday, August 14th. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company. CVS Health Corporation currently has a consensus rating of “Buy” and a consensus target price of $90.83.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.